RecruitingPhase 4NCT03717623

Posaconazole Pharmacokinetics in Patients Receiving Chemotherapy or Stem Cell Transplants

Pharmacokinetics Study of Posaconazole in Haematology Patients Receiving Standard of Care Treatment With Oral Posaconazole Prophylaxis for Invasive Fungal Infection

Sponsor

Melbourne Health

Enrollment

100 participants

Start Date

Aug 1, 2019

Study Type

INTERVENTIONAL

Conditions

Invasive Aspergillosis Fungal Infection Pharmacokinetics Prophylaxis Invasive Candidiases Posaconazole Invasive Mycosis

Summary

The purpose of the study is to investigate the pharmacokinetics of oral dosage of Posaconazole which is routinely administered as a standard care prophylaxis for patients undergoing cancer treatments.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Posaconazole pharmacokinetics for people with fungal infection, invasive aspergillosis, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGPosaconazole pharmacokinetics

Blood samples will be collected on Days 7, 14 and 21 from the onset of Posaconazole prophylactic treatment If significant diarrhoea occurs, additional blood samples will be collected twice weekly until symptoms resolve. All blood samples will be used for Posaconazole pharmacokinetics study.